Previous study has demonstrated that the introduction of functional hemagglutinin-neuraminidase (HN) molecules by NDV on the surface of tumour cells facilitates the CD8 + T-cell response through their cell binding and the HN could also act as a ligand for NKp46 and NKp44 receptors on human NK cells, directly activating NK cells and contributing to the anti-tumoral effect of NDV [37, 40]. The gene discussed is NCR1; the disease is neoplasm.